Article ID | Journal | Published Year | Pages | File Type |
---|---|---|---|---|
3025258 | Seminars in Thoracic and Cardiovascular Surgery | 2013 | 6 Pages |
Abstract
Stereotactic ablative radiotherapy, also known as stereotactic body radiation therapy, has been developed as an innovative therapy for stage I non-small cell lung cancer and has now emerged as a standard treatment option for medically inoperable patients through careful analysis using prospective multi-institutional trials. We review and update the evidence for use of stereotactic ablative radiotherapy in medically inoperable patients with stage I lung cancer, and its possible extension of use to operable patients, from the perspectives of an experienced radiation oncologist and a thoracic surgeon.
Related Topics
Health Sciences
Medicine and Dentistry
Cardiology and Cardiovascular Medicine
Authors
Robert D. Timmerman, Hiran C. Fernando,